These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1722 related items for PubMed ID: 8536275

  • 1. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
    Mulder WM, Stukart MJ, Roos M, van Lier RA, Wagstaff J, Scheper RJ, Bloemena E.
    Cancer Immunol Immunother; 1995 Nov; 41(5):293-301. PubMed ID: 8536275
    [Abstract] [Full Text] [Related]

  • 2. Efficient expansion of tumor-infiltrating lymphocytes from solid tumors by stimulation with combined CD3 and CD28 monoclonal antibodies.
    Flens MJ, Mulder WM, Bril H, von Blomberg van de Flier MB, Scheper RJ, van Lier RA.
    Cancer Immunol Immunother; 1993 Oct; 37(5):323-8. PubMed ID: 8402736
    [Abstract] [Full Text] [Related]

  • 3. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M.
    Cancer; 1994 Aug 15; 74(4):1275-82. PubMed ID: 7914469
    [Abstract] [Full Text] [Related]

  • 4. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B, Ceuppens JL.
    Clin Exp Immunol; 1997 Sep 15; 109(3):501-9. PubMed ID: 9328129
    [Abstract] [Full Text] [Related]

  • 5. T cell receptor gene rearrangements and cytotoxic activities of clones isolated from tumour-infiltrating lymphocytes (TIL) from melanoma patients.
    Pandolfi F, Boyle LA, Trentin L, Oliva A, Kurnick JT.
    Clin Exp Immunol; 1994 Jan 15; 95(1):141-7. PubMed ID: 8287599
    [Abstract] [Full Text] [Related]

  • 6. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.
    Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G.
    Cancer Immunol Immunother; 1992 Jan 15; 34(4):241-51. PubMed ID: 1311218
    [Abstract] [Full Text] [Related]

  • 7. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT, Pinto CE, Gifford JD, Kurnick JT, Kradin RL.
    J Immunol; 1989 Nov 15; 143(10):3404-11. PubMed ID: 2509557
    [Abstract] [Full Text] [Related]

  • 8. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K, Harada M, Okamoto T, Takenoyama M, Ito O, Matsuzaki G, Nomoto K.
    Cancer Immunol Immunother; 1995 Dec 15; 41(6):339-47. PubMed ID: 8635191
    [Abstract] [Full Text] [Related]

  • 9. Lymphokine production by human melanoma tumor-infiltrating lymphocytes.
    Salmeron MA, Morita T, Seki H, Platsoucas CD, Itoh K.
    Cancer Immunol Immunother; 1992 Dec 15; 35(3):211-7. PubMed ID: 1386286
    [Abstract] [Full Text] [Related]

  • 10. Tumor-infiltrating CD3- NK cells are more effective than CD3+ T cells in killing autologous melanoma cells.
    Azogui O, Avril MF, Margulis A, Guillard M, Caillou B, Prade M.
    J Invest Dermatol; 1991 Sep 15; 97(3):425-9. PubMed ID: 1831465
    [Abstract] [Full Text] [Related]

  • 11. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach AC, Legha SS, Balch CM, Ross MI, Augustus LB, Itoh K.
    J Immunother (1991); 1991 Oct 15; 10(5):313-25. PubMed ID: 1790139
    [Abstract] [Full Text] [Related]

  • 12. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG.
    J Immunother; 2011 Apr 15; 34(3):236-50. PubMed ID: 21389874
    [Abstract] [Full Text] [Related]

  • 13. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S, Etto T, Rodríguez-Cruz T, Li Y, Wu C, Fulbright OJ, Hwu P, Radvanyi L, Lizée G.
    J Immunother; 2010 May 15; 33(4):371-81. PubMed ID: 20386469
    [Abstract] [Full Text] [Related]

  • 14. Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy.
    Goedegebuure PS, Zuber M, Leonard-Vidal DL, Burger UL, Cusack JC, Chang MP, Douville LM, Eberlein TJ.
    Surg Oncol; 1994 Apr 15; 3(2):79-89. PubMed ID: 7952395
    [Abstract] [Full Text] [Related]

  • 15. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N, Andersen MH, Wenandy L, Dombernowsky SL, Kiss K, Sørensen CH, Therkildsen MH, Von Buchwald C, Andersen E, Straten PT, Svane IM.
    Cytotherapy; 2011 Aug 15; 13(7):822-34. PubMed ID: 21428850
    [Abstract] [Full Text] [Related]

  • 16. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck.
    Hald J, Rasmussen N, Claesson MH.
    Cancer Immunol Immunother; 1995 Oct 15; 41(4):243-50. PubMed ID: 7489567
    [Abstract] [Full Text] [Related]

  • 17. Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies.
    Nijhuis EW, vd Wiel-van Kemenade E, Figdor CG, van Lier RA.
    Cancer Immunol Immunother; 1990 Oct 15; 32(4):245-50. PubMed ID: 2175673
    [Abstract] [Full Text] [Related]

  • 18. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
    Gervois N, Heuze F, Diez E, Jotereau F.
    Eur J Immunol; 1990 Apr 15; 20(4):825-31. PubMed ID: 1971794
    [Abstract] [Full Text] [Related]

  • 19. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma.
    Koo AS, Tso CL, Shimabukuro T, Peyret C, deKernion JB, Belldegrun A.
    J Immunother (1991); 1991 Oct 15; 10(5):347-54. PubMed ID: 1790142
    [Abstract] [Full Text] [Related]

  • 20. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L.
    PLoS One; 2013 Oct 15; 8(4):e60031. PubMed ID: 23560068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 87.